Skip to main content

Table 2 Antibody model parameters

From: Modelling population-level impact to inform target product profiles for childhood malaria vaccines

Scenario tdose 4 (months) ABdose 4 (EU/mL) V max α β
A: RTS,S/AS01 phase 3 18 277 0.93 0.74 99.2
B: Intermediate 13 450 0.93 0.85 85.0
C: Modified 8 621 0.93 0.95 70.0
  1. These parameters correspond to three vaccine scenarios: an RTS,S/AS01 phase 3 efficacy profile (A), a modified profile based on the phase 2a challenge study (C) [6, 7] and an intermediate profile (B). The antibody titre and efficacy profiles are provided in Additional file 1: Figure S6 and Fig. 4, respectively. The parameter ABdose 4 represents the antibody titre following the fourth vaccine dose at time tdose 4